The Latest Breaking News from Vir Biotechnology

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits.

A Relative Strength Rating upgrade for Vir Biotechnology shows improving technical performance.

Vir Biotechnology inked a deal Tuesday worth up to $1 billion for its experimental flu treatment, leading Vir stock to surge.

Vir Biotechnology Inc shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

What Defines a Value Stock?

Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $3.78.

What are Value Stocks?

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…